应对不断变化的利益相关者需求以及通过IQVIA的集成技术服务和分析驱动的产品增加成本限制的挑战。
While the nation’s primary healthcare focus remains on the COVID-19 pandemic as we move through the third year of its disruptive effects and the death toll approaches 1 million, other important dynamics are playing out with respect to the utilization of health services, the use of prescription medicines, and the associated spending levels, including patient out-of-pocket costs. Understanding these elements of the health system and how they may evolve over the next five years remains critical to decision-makers and stakeholders – including patients.
这份年度趋势报告 -在美国2022年使用药物- 旨在在短期和长期含义的一系列问题上提供有关相关信息的基础。它包括医疗服务利用指数,该指数跟lol买外围用什么软件踪一系列影响使用药物使用的医疗保健活动。
Spending and growth drivers reflect the significant differences in levels of spending by stakeholders as discounts and rebates distort these trends even as the most impactful driver has been the amount spent on COVID-19 vaccines and therapeutics. An overview of patient out-of-pocket costs shows that while most patients’ costs are falling, a small proportion have high costs which impact their use of medicines with implications for their health outcomes.
未来几年的前景包括大流行的预期终结以及使用驱动因素和整体支出和关键治疗领域的重大转变。
应对不断变化的利益相关者需求以及通过IQVIA的集成技术服务和分析驱动的产品增加成本限制的挑战。